ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

Stock Information for Southland Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Southland Holdings Inc.

Orion Group Holdings Reports First Quarter 2025 Results
Orion Group Holdings to Report First Quarter 2025 Financial Results on Tuesday, April 29
Orion Group Holdings Reports Fourth Quarter and Full Year 2024 Results
Orion Group Holdings Awarded $211.7 Million in New Contracts
Orion Group Holdings to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
Orion Group Holdings Announces Contract Awards Valued at Approximately $111 Million

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.